Lupo, Maria Giovanna

Glucagon-like peptide-1 receptor agonists and muscle mass effects

Ceasovschih, A., Asaftei, A., Lupo, M. G., Kotlyarov, S., Bartušková, H., Balta, A., Sorodoc, V., Sorodoc, L., & Banach, M. (2025) · Pharmacological Research

Nutrition and Health in AgingDiabetes Treatment and Management

Cited by 64

PCSK9 ablation attenuates Aβ pathology, neuroinflammation and cognitive dysfunctions in 5XFAD mice

Vilella, A., Bodria, M., Papotti, B., Zanotti, I., Zimetti, F., Remaggi, G., Elviri, L., Potì, F., Ferri, N., Lupo, M. G., et al. (2024) · Brain, Behavior, and Immunity

Alzheimer's disease research and treatmentsNeuroinflammation and Neurodegeneration Mechanisms

Cited by 43

PCSK9 affects astrocyte cholesterol metabolism and reduces neuron cholesterol supplying in vitro: potential implications in Alzheimer’s disease

Papotti, B., Adorni, M. P., Marchi, C., Zimetti, F., Ronda, N., Panighel, G., Lupo, M. G., Vilella, A., Giuliani, D., Ferri, N., et al. (2022) · International Journal of Molecular Sciences

Alzheimer's disease research and treatmentsCholesterol and Lipid Metabolism

Cited by 41

Neuronal PCSK9 regulates cognitive performances via the modulation of ApoER2 synaptic localization

Pelucchi, S., Da Dalt, L., De Cesare, G., Stringhi, R., D’Andrea, L., La Greca, F., Cambria, C., Vandermeulen, L., Zianni, E., Musardo, S., et al. (2025) · Pharmacological Research

Neuroscience and Neuropharmacology ResearchAlzheimer's disease research and treatments

Cited by 12

Effect of natural and synthetic PCSK9 inhibitors on Alzheimer’s disease-related parameters in human cerebral cell models

Ugolotti, M., Papotti, B., Adorni, M. P., Giannessi, L., Rossi, I., Lupo, M. G., Panighel, G., Ferri, N., Kukula-Koch, W., Vilella, A., et al. (2024) · Atherosclerosis

Alzheimer's disease research and treatmentsNeuroinflammation and Neurodegeneration Mechanisms

Cited by 1